Literature DB >> 28910797

The Rationale for Expanded Hemodialysis Therapy (HDx).

Colin A Hutchison, Martin Wolley.   

Abstract

As dialysis membrane technologies have advanced, the ability to clear increasing numbers of uremic toxins has occurred. To date, however, the class of uremic toxins known as large middle-molecules has been classified as "difficult to remove." Expanded hemodialysis utilizes a new generation of high-retention-onset hemodialysis membranes; these membranes provide the ability to remove large middle-molecules effectively for the first time, without significant albumin loss. In this review, we evaluate the removal of large middle-molecules by the new high-retention-onset membranes, the clinical relevance of these molecules, and how expanded hemodialysis can be prescribed.
© 2017 S. Karger AG, Basel.

Mesh:

Substances:

Year:  2017        PMID: 28910797     DOI: 10.1159/000479262

Source DB:  PubMed          Journal:  Contrib Nephrol        ISSN: 0302-5144            Impact factor:   1.580


  9 in total

1.  Cardiovascular Risk Comparison between Expanded Hemodialysis Using Theranova and Online Hemodiafiltration (CARTOON): A Multicenter Randomized Controlled Trial.

Authors:  Yeonhee Lee; Myoung-Jin Jang; Junseok Jeon; Jung Eun Lee; Wooseong Huh; Bum Soon Choi; Cheol Whee Park; Ho Jun Chin; Chae Lin Kang; Dong Ki Kim; Seung Seok Han; Kwon Wook Joo
Journal:  Sci Rep       Date:  2021-05-24       Impact factor: 4.379

Review 2.  Molecular Mechanisms of Premature Aging in Hemodialysis: The Complex Interplay Between Innate and Adaptive Immune Dysfunction.

Authors:  Vincenzo Losappio; Rossana Franzin; Barbara Infante; Giulia Godeas; Loreto Gesualdo; Alberto Fersini; Giuseppe Castellano; Giovanni Stallone
Journal:  Int J Mol Sci       Date:  2020-05-12       Impact factor: 5.923

3.  A Pharmacokinetic Study Comparing the Clearance of Vancomycin during Haemodialysis Using Medium Cut-Off Membrane (Theranova) and High-Flux Membranes (Revaclear).

Authors:  Hussain Allawati; Linda Dallas; Sreejith Nair; Janine Palmer; Shaiju Thaikandy; Colin Hutchison
Journal:  Toxins (Basel)       Date:  2020-05-12       Impact factor: 4.546

4.  Retention of beneficial molecules and coagulation factors during haemodialysis and haemodiafiltration.

Authors:  Manuel Voigt; Michael Gebert; Ulrike Haug; Michael Hulko; Markus Storr; Adriana Boschetti-de-Fierro; Werner Beck; Bernd Krause
Journal:  Sci Rep       Date:  2019-04-23       Impact factor: 4.379

5.  Impact of Expanded Hemodialysis Using Medium Cut-off Dialyzer on Quality of Life: Application of Dynamic Patient-Reported Outcome Measurement Tool.

Authors:  Jarrin D Penny; Patricia Jarosz; Fabio R Salerno; Sandrine Lemoine; Christopher W McIntyre
Journal:  Kidney Med       Date:  2021-07-29

6.  Clinical Assessment of Dialysis Recovery Time and Symptom Burden: Impact of Switching Hemodialysis Therapy Mode.

Authors:  Stephanie Bolton; Rachel Gair; Lars-Göran Nilsson; Michael Matthews; Louanne Stewart; Natasha McCullagh
Journal:  Patient Relat Outcome Meas       Date:  2021-11-04

7.  Economic evaluation of expanded hemodialysis with the Theranova 400 dialyzer: A post hoc evaluation of a randomized clinical trial in the United States.

Authors:  Michael J Blackowicz; Luke Falzon; Werner Beck; Ha Tran; Daniel E Weiner
Journal:  Hemodial Int       Date:  2022-04-19       Impact factor: 1.543

8.  Efficacy and Safety of Expanded Hemodialysis with the Theranova 400 Dialyzer: A Randomized Controlled Trial.

Authors:  Daniel E Weiner; Luke Falzon; Line Skoufos; Angelito Bernardo; Werner Beck; Mengqi Xiao; Ha Tran
Journal:  Clin J Am Soc Nephrol       Date:  2020-08-25       Impact factor: 8.237

Review 9.  Expanded haemodialysis: from operational mechanism to clinical results.

Authors:  Claudio Ronco; Nicola Marchionna; Alessandra Brendolan; Mauro Neri; Anna Lorenzin; Armando J Martínez Rueda
Journal:  Nephrol Dial Transplant       Date:  2018-10-01       Impact factor: 5.992

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.